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Th   e European Clinical Trials Directive includes a 
provision for informed consent from the patient or proxy 
consent from a legal representative in drug trials [1]. 
Although there is no doubt that informed consent is a 
valuable tool to protect patients’ rights in clinical trials, it 
is only very rarely possible to obtain a valid informed 
consent in emergencies, where a life-saving intervention 
is required within seconds to minutes. If pursued, and 
the consent is obtained from either the patient or a proxy, 
it cannot be considered valid; because of the obviously 
stressful situation, absence of duress cannot be pre-
supposed, either with regard to a patient’s or a relative’s 
(proxy) consent. In contrast to the most recent revision 
of the Declaration of Helsinki [2], the European Directive 
oﬀ  ers no means of exemption from this requirement [1]. 
Th   us, while the requirement of informed consent 
hampers clinical trials on potentially life-saving drugs in 
critical care settings [3], it does not protect the patient’s 
rights in this context.
Informed consent is instituted in human experimenta-
tion in order to respect the autonomy of the research 
subject. Autonomy is a presupposition of agency and 
solely refers to agents who can understand and choose 
what they do [4]. Informed consent is not in itself an 
ethical principle, but an important procedure that per-
mits human experimentation with the aim of beneﬁ  ting 
society and future patients, without violating the basic 
rights of research subjects. However, since both medical 
treatment and, consequently, medical research also 
extend to those with incomplete autonomy, such as 
incapacitated critically ill patients, respect for autonomy 
cannot be considered the only or most important ethical 
principle. Other principles that express the basic rights of 
the research subject must be considered. In ethical terms, 
these basic rights are expressed in the ‘categorical 
imperative’, which states that any human being possesses 
an inherent value and dignity and must be treated with 
respect, and therefore ‘always at the same time as an end 
and never merely as a means to an end’ [5]. To sustain 
this principle in subjects with incomplete autonomy that 
cannot consent to research, these subjects must be 
ensured adequate protection that reﬂ  ects their vulnera-
bility [6]. Instead of insisting on a prospective informed 
consent regardless of the context, it may therefore be 
worthwhile to accept the premise that informed consent 
or proxy consent cannot be obtained in all types of 
research. It is by no means a sine qua non, and comprises 
only one of three ethically relevant elements in human 
experimentation, the other two being risk assessment 
and selection of research subjects [6].
With regard to risk assessment, the accepted risks are 
tightly linked to the autonomy of the subject. Th  us, 
higher risks are accepted when the subject is capable of 
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the principle of extra protection to patients with in-
complete autonomy, risks must be minimised in incapa-
ci  tated patients. Th  ese risks relate to both therapeutic 
and non-therapeutic procedures of the trial [6]. 
Th   erapeutic procedures are study interventions instituted 
with the intent of providing direct beneﬁ  t to the patient. 
In drug trials, therapeutic procedures comprise the 
administration of drugs that have the prospect of 
beneﬁ  ting the patient. Th   ese must pass the test of clinical 
equipoise, which signiﬁ  es that the two interventions are 
roughly equivalent, in the sense that a genuine un  cer-
tainty concerning the comparable merits and disadvan-
tages of each trial arm exists in the expert medical 
community [6]. Th   e potential risks of these interventions 
are thus to be considered in light of their potential beneﬁ  t 
for the individual patient. Non-therapeutic procedures 
are those interventions that are not instituted with 
therapeutic intent and are only intended to answer 
scientiﬁ   c questions of the study, such as additional 
laboratory tests and imaging to monitor treatment eﬀ  ects 
in detail. Since the patient cannot consent to these risks, 
these must be reduced to minimal risks [6]. Minimal risk 
implies that the probability and magnitude of harm or 
discomfort anticipated in the trial are not greater than 
those encountered by normal persons in daily life; a 
routine physical examination with blood sampling is 
considered a classical example of a procedure that 
involves a minimal risk [6]. Since the risks of the thera-
peutic procedures are unaﬀ  ected by trial partici  pation, 
the only additional risk imposed by inclusion in the trial 
is equivalent to that associated with a routine physical 
examination. As previously stated by Charles Weijer in 
Critical Care [7], such a risk assessment that distin-
guishes therapeutic from non-therapeutic components of 
the study shifts the focus from the potentially deleterious 
complications of critical illness per se to the actual risks 
imposed by participation in the study.
As for the selection of patients, the requirement of 
adequate protection entails that exploitation of these 
patients as easily accessible research subjects due to their 
impaired autonomy must be prevented. Th   us, the overall 
aim of the research must be to speciﬁ  cally improve care 
of this patient group. Furthermore, it must be essential to 
the design and conclusions of the research that it is 
conducted under circumstances where it is by no means 
possible to obtain a valid informed consent [6].
If we want treatment of critically ill patients to be based 
on evidence-based principles, it is necessary to change 
the European Directive so that drug trials can be initiated 
under circumstances where it is impossible to obtain a 
valid informed consent from either the patient or a proxy. 
It is paramount that we ensure adequate protection of the 
individual patient in such studies, which is achieved by 
focusing on the scientiﬁ   c content, rather than the 
consent, which is neither suﬃ   cient nor necessary. Th  e 
Ethical Review Boards should be equipped to determine 
whether participation in a trial is by any means contrary 
to the best interest of a given patient, by critically 
reviewing and monitoring study protocols in which a 
waiver of consent is deemed necessary. Th  is permits 
clinical trials in critical care settings while ensuring that 
the individual patient is treated respectfully in accor-
dance with the categorical imperative.
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